[Clinical study of fluconazole for systemic fungal infections with hematological disorders].
Fluconazole (FLCZ) was administered orally or intravenously to 161 patients with systemic fungal infections complicated with hematological disorders and it was possible to evaluate clinical efficacies in 109 patients. Systemic fungal infections were documented in 48 patients and suspected in 61 patients. The overall clinical efficiency rates were 43.8% (21/48) in patients with documented fungal infections, and 55.7% (34/61) in patients with suspected fungal infections. Therefore, the overall clinical efficacy rate was 50.5% (55/109). Side effects were observed in 5 patients with an incident rate of 3.1% (5/161), but there was none of them was serious. These results indicate that FLCZ is an agent with good potential in treatment of systemic fungal infections in patients with hematological disorders.
Kitamura
S
S
Third Department of Internal Medicine, University of Tokyo.
Miyakawa
K
K
Wakabayashi
Y
Y
Urabe
A
A
Sato
H
H
Ohbayashi
Y
Y
Takaku
F
F
Togawa
A
A
Shindo
E
E
Aoki
I
I
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000150:complications*; D008223:Lymphoma / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*
D015725:Fluconazole